← 返回前沿论文

通过代谢物感应受体将细胞毒性淋巴细胞重定向至乳腺癌肿瘤

英文原题:Redirecting cytotoxic lymphocytes to breast cancer tumors via metabolite-sensing receptors.

PubMed 2025/03/25(内容时间) bioRxiv

研究概要

细胞毒性淋巴细胞向实体瘤的浸润不足,限制了免疫疗法与细胞疗法的疗效。

中文摘要

细胞毒性淋巴细胞向实体瘤浸润不足,限制了免疫疗法和细胞疗法的疗效。本研究报告一种可编程机制:通过工程化改造自然杀伤(NK)细胞和T细胞,使其表达孤儿型及代谢物感应型G蛋白偶联受体(GPCR),促使细胞向乳腺癌肿瘤募集。首先,在NK-92细胞中开展体内和体外CRISPR激活筛选,鉴定出GPR183、GPR84、GPR34、GPR18、FPR3和LPAR2为增强乳腺癌趋化及肿瘤浸润的主要受体。这些基因赋予NK细胞和T细胞感知并迁移至乳腺癌释放的趋化代谢物(如7α,25-二羟基胆固醇)及其他因子的能力。基于Perturb-seq和功能研究,GPR183还可增强效应功能;工程化表达GPR183的NK细胞和CAR-NK细胞向乳腺癌迁移、浸润并控制肿瘤的能力均有所提高。本研究揭示了基于代谢物的肿瘤免疫细胞募集机制,为空间靶向细胞疗法开辟了新途径。

展开英文摘要原文

Insufficient infiltration of cytotoxic lymphocytes to solid tumors limits the efficacy of immunotherapies and cell therapies. Here, we report a programmable mechanism to mobilize Natural Killer (NK) and T cells to breast cancer tumors by engineering these cells to express orphan and metabolite-sensing G protein-coupled receptors (GPCRs). First, in vivo and in vitro CRISPR activation screens in NK-92 cells identified GPR183 , GPR84 , GPR34 , GPR18 , FPR3 , and LPAR2 as top enhancers of both tumor infiltration and chemotaxis to breast cancer. These genes equip NK and T cells with the ability to sense and migrate to chemoattracting metabolites such as 7 ,25-dihydroxycholesterol and other factors released from breast cancer. Based on Perturb-seq and functional investigations, GPR183 also enhances effector functions, such that engineering NK and CAR NK cells to express GPR183 enhances their ability to migrate to, infiltrate, and control breast cancer tumors. Our study uncovered metabolite-based tumor immune recruitment mechanisms, opening avenues for spatially targeted cell therapies.

论文信息

作者
Kim YM、Akana RV、Sun C、Laveroni O、Jerby L
单位
Department of Genetics, Stanford University School of Medicine; Stanford, CA, USA.United States
文献类型
预印本
期刊
bioRxiv : the preprint server for biology2025 Mar 25
原文标识
PubMed 40196673 · DOI 10.1101/2025.03.21.644686